The average one-year price target for Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) has been revised to 16.03 / share. This is an increase of 8.91% from the prior estimate of 14.72 dated July 5, 2023.
The price target is an average of many targets provided by analysts. The latest targets range from a low of 9.09 to a high of 36.75 / share. The average price target represents an increase of 13.52% from the latest reported closing price of 14.12 / share.
What is the Fund Sentiment?
There are 340 funds or institutions reporting positions in Recursion Pharmaceuticals Inc -. This is an increase of 12 owner(s) or 3.66% in the last quarter. Average portfolio weight of all funds dedicated to RXRX is 0.31%, a decrease of 59.86%. Total shares owned by institutions decreased in the last three months by 5.04% to 134,587K shares. 
The put/call ratio of RXRX is 0.54, indicating a bullish outlook.
What are Other Shareholders Doing?
Baillie Gifford holds 25,098K shares representing 12.54% ownership of the company. In it's prior filing, the firm reported owning 25,136K shares, representing a decrease of 0.15%. The firm increased its portfolio allocation in RXRX by 5.35% over the last quarter.
Kinnevik AB holds 10,406K shares representing 5.20% ownership of the company. In it's prior filing, the firm reported owning 7,653K shares, representing an increase of 26.45%. The firm increased its portfolio allocation in RXRX by 46.04% over the last quarter.
MIC Capital Management UK LLP holds 8,452K shares representing 4.22% ownership of the company. No change in the last quarter.
Data Collective IV GP holds 5,941K shares representing 2.97% ownership of the company. No change in the last quarter.
Laurion Capital Management holds 4,826K shares representing 2.41% ownership of the company. No change in the last quarter.
Recursion Pharmaceuticals Background Information
(This description is provided by the company.)
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Central to its mission is the Recursion Operating System, or Recursion OS, that combines an advanced infrastructure layer to generate what Recursion believes is one of the world's largest and fastest-growing proprietary biological and chemical datasets and the Recursion Map, a suite of custom software, algorithms, and machine learning tools that the company uses to explore foundational biology unconstrained by human bias and navigate to new biological insights which may accelerate its programs. biotechnology company scaling more like a technology company.
Additional reading:
- STOCK PURCHASE AGREEMENT BY AND BETWEEN RECURSION PHARMACEUTICALS, INC., THE PURCHASER AS SET FORTH HEREIN JULY 11, 2023 TABLE OF CONTENTS
- REGISTRATION RIGHTS AGREEMENT
- Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
- Early June 2023 This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These forward-looking
- Registration Agreement dated May 25, 2023 by and among the Registrant, Recursion Canada Inc., and certain shareholders of Cyclica Inc.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
